drugset / Trial / NCT00641771

4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230)

NCT00641771

Phase 1 Completed 56 enrolled Organon and Co
RandomizedSingle-groupDouble-blindTreatment

Summary

To compare change in fractional calcium absorption following administration of MK0217A relative to matching placebo, in postmenopausal women with osteoporosis

Timeline

Start
2004-05
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg Oral
Subject Cholecalciferol Other / unclassified 2800 iu Oral

Indications